FCH
ALXN

Freestone Capital Holdings’s Alexion Pharmaceuticals ALXN Stock Holding History

Freestone Capital Holdings’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,018
Closed -$371K – 448
2021
Q2 		$371K Sell
2,018
-626
-24% -$107K 0.02% 308
2021
Q1 		$404K Sell
2,644
-7,916
-75% -$1.22M 0.02% 293
2020
Q4 		$1.65M Buy
10,560
+57
+0.5% +$7.33K 0.1% 170
2020
Q3 		$1.2M Sell
10,503
-274
-3% -$29.6K 0.08% 178
2020
Q2 		$1.21M Buy
10,777
+492
+5% +$52.2K 0.01% 188
2020
Q1 		$923K Buy
10,285
+1,257
+14% +$123K 0.02% 199
2019
Q4 		$976K Sell
9,028
-325
-3% -$34.8K 0.02% 265
2019
Q3 		$916K Buy
9,353
+494
+6% +$55.7K 0.02% 268
2019
Q2 		$1.16M Buy
8,859
+725
+9% +$93.4K 0.03% 223
2019
Q1 		$1.1M Buy
8,134
+3,776
+87% +$470K 0.07% 209
2018
Q4 		$424K Buy
4,358
+2,402
+123% +$284K 0.03% 311
2018
Q3 		$272K Buy
+1,956
New +$245K ﹤0.01% 344

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Freestone Capital Holdings's ALXN Position: Q3 2021 in Review

Freestone Capital Holdings sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,018 shares — an estimated $371K sold.

Freestone Capital Holdings first reported a position in ALXN in Q3 2018 and held it in 12 quarters. The position peaked at $1.65M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Freestone Capital Holdings reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Freestone Capital Holdings sold 2,018 Alexion Pharmaceuticals shares in Q3 2021, an estimated $371K.
  • Freestone Capital Holdings first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 12 quarters.
  • Freestone Capital Holdings's Alexion Pharmaceuticals position peaked at $1.65M in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Freestone Capital Holdings's 13F filing for Q3 2021, filed 15 Nov 2021.